Richard James Whitley, MD, is a Distinguished Professor of Pediatrics and a Professor of Microbiology, Medicine, and Neurosurgery at the University of Alabama at Birmingham (UAB). He is also Loeb Eminent Scholar Chair in Pediatrics; Co-Director of the Division of Pediatric Infectious Diseases; Vice-Chair of the Department of Pediatrics; Senior Scientist in the Department of Gene Therapy; Scientist at the Cancer Research and Training Center; Faculty at the Gene Therapy Center; Senior Leader of the Pediatric Oncology Program at the Comprehensive Cancer Center; Director of the UAB Center for Emerging Drug Discovery; and Co-Founder and Co-Director of the Alabama Drug Discovery Alliance.
Dr. Whitley received his medical degree from George Washington University. He then served a residency in pediatrics and
a fellowship in infectious diseases/virology at the University of Alabama at Birmingham.
Dr. Whitley is board certified by the American Board of Pediatrics, with a subspecialty in infectious diseases. He is Associate Editor of Journal of Infectious Diseases and is a member of the editorial board of many other scholarly journals, including Antimicrobial Agents and Chemotherapy, Reviews of Infectious Diseases, Human Gene Therapy, and Current Opinion in Infectious Diseases.
Dr. Whitley’s major research interests include antiviral therapies directed against medically important viral diseases of children and adults, including neonatal herpes simplex virus infection, herpes simplex encephalitis, herpes zoster, enteroviral infections of the newborn, therapeutic interventions for congenital cytomegalovirus infections, hepatitis C, and respiratory virus diseases in the immunocompromised host; and the translation of molecular biology to clinical application, particularly in the development of human monoclonal antibodies for therapy of herpesvirus infections and engineering of herpes simplex virus for gene therapy. He is a past President of the Infectious Diseases Society of America (IDSA) and was the inaugural recipient of the Distinguished Clinical Research Scholar and Educator in Residence at the NIH Clinical Center. In addition, he is the author or coauthor of more than 350 published articles and 240 book chapters.
What is Richard James Whitley's net worth?
The estimated net worth of Richard James Whitley is at least $320.25 as of December 8th, 2022. Dr. Whitley owns 700 shares of Virios Therapeutics stock worth more than $320 as of April 25th. This net worth evaluation does not reflect any other assets that Dr. Whitley may own. Learn More about Richard James Whitley's net worth.
How do I contact Richard James Whitley?
Has Richard James Whitley been buying or selling shares of Virios Therapeutics?
Richard James Whitley has not been actively trading shares of Virios Therapeutics within the last three months. Most recently, Richard James Whitley sold 1,800 shares of the business's stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $0.26, for a transaction totalling $468.00. Following the completion of the sale, the director now directly owns 700 shares of the company's stock, valued at $182. Learn More on Richard James Whitley's trading history.
Who are Virios Therapeutics' active insiders?
Are insiders buying or selling shares of Virios Therapeutics?
In the last twelve months, Virios Therapeutics insiders bought shares 2 times. They purchased a total of 40,335 shares worth more than $51,185.50. The most recent insider tranaction occured on August, 21st when Director William Pridgen bought 15,335 shares worth more than $19,935.50. Insiders at Virios Therapeutics own 11.7% of the company.
Learn More about insider trades at Virios Therapeutics. Information on this page was last updated on 8/21/2023.
